Advancing Federal Coordination to Address Drug Shortages

Area of Science:

• Health Policy
• Pharmaceutical Sciences
• Oncology

Background:

• Persistent shortages of essential medicines, especially generic oncology drugs, critically impact cancer care and patient safety in the U.S.
• Numerous federal agencies and industry experts have identified similar recommendations to address these shortages.

Purpose of the Study:

• To synthesize findings from high-level reports on essential medicine shortages.
• To identify barriers to progress, such as misaligned agency roles and priorities.
• To propose a practical path forward for ensuring drug availability.

Main Methods:

• Synthesis of key findings from federal agency and industry expert reports.
• Analysis of case studies (cisplatin, vincristine, methotrexate) to illustrate the impact of shortages.
• Drawing parallels with successful coordination strategies during the COVID-19 pandemic.

Main Results:

• Multiple reports converge on recommendations like a unified essential medicines list, transparent supply chain monitoring, domestic manufacturing incentives, and federal coordination.
• Misalignment in agency roles and priorities poses a significant barrier to sustained progress in addressing drug shortages.
• Specific drug shortages (cisplatin, vincristine, methotrexate) highlight the severe consequences of inaction.

Conclusions:

• Establishing a central federal coordinating body is crucial.
• Legislating an essential medicines list using a criticality-reach-vulnerability framework is recommended.
• Reforming procurement incentives and expanding the Strategic National Stockpile are vital steps.